Bridgeway Capital Management, LLC Syros Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.69 - $1.21 $51,749 - $90,750	-75,000 Reduced 44.12%	95,000 $91,000
Q4 2021 Feb 14, 2022	BUY	$3.26 - $4.66 $554,200 - $792,200	170,000 New	170,000 $554,000
Q1 2020 May 15, 2020	SELL	$4.46 - $9.2 $148,518 - $306,360	-33,300 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$5.5 - $9.75 $220,000 - $390,000	-40,000 Reduced 54.57%	33,300 $308,000
Q1 2019 May 15, 2019	BUY	$5.51 - $9.59 $40,774 - $70,966	7,400 Added 11.23%	73,300 $670,000
Q4 2018 Feb 14, 2019	SELL	$5.55 - $11.34 $111,000 - $226,800	-20,000 Reduced 23.28%	65,900 $367,000
Q2 2018 Aug 14, 2018	SELL	$10.16 - $13.65 $140,208 - $188,370	-13,800 Reduced 13.84%	85,900 $877,000
Q1 2018 May 15, 2018	BUY	$9.47 - $12.98 $944,159 - $1.29 Million	99,700 New	99,700 $1.29 Million

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $4.86M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.